Overview of bladder heating technology: matching capabilities with clinical requirements
- PMID: 26939993
- PMCID: PMC4968693
- DOI: 10.3109/02656736.2016.1141239
Overview of bladder heating technology: matching capabilities with clinical requirements
Abstract
Moderate temperature hyperthermia (40-45°C for 1 h) is emerging as an effective treatment to enhance best available chemotherapy strategies for bladder cancer. A rapidly increasing number of clinical trials have investigated the feasibility and efficacy of treating bladder cancer with combined intravesical chemotherapy and moderate temperature hyperthermia. To date, most studies have concerned treatment of non-muscle-invasive bladder cancer (NMIBC) limited to the interior wall of the bladder. Following the promising results of initial clinical trials, investigators are now considering protocols for treatment of muscle-invasive bladder cancer (MIBC). This paper provides a brief overview of the devices and techniques used for heating bladder cancer. Systems are described for thermal conduction heating of the bladder wall via circulation of hot fluid, intravesical microwave antenna heating, capacitively coupled radio-frequency current heating, and radiofrequency phased array deep regional heating of the pelvis. Relative heating characteristics of the available technologies are compared based on published feasibility studies, and the systems correlated with clinical requirements for effective treatment of MIBC and NMIBC.
Keywords: Bladder cancer; electromagnetic heating; hyperthermia; intravesical heating; thermo-chemotherapy.
Conflict of interest statement
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.
Figures
Similar articles
-
Chemohyperthermia in non-muscle-invasive bladder cancer: An overview of the literature and recommendations.Int J Hyperthermia. 2016 Jun;32(4):363-73. doi: 10.3109/02656736.2016.1155760. Epub 2016 Apr 7. Int J Hyperthermia. 2016. PMID: 27056069 Review.
-
[Intravesical instillations in non-muscle-invasive bladder cancer (NMIBC). Prospects for thermochemotherapy].Prog Urol. 2016 Nov;26(14):860-864. doi: 10.1016/j.purol.2016.09.057. Epub 2016 Oct 3. Prog Urol. 2016. PMID: 27712914 French.
-
Intravesical radiofrequency-induced hyperthermia combined with chemotherapy for non-muscle-invasive bladder cancer.Int J Hyperthermia. 2016 Jun;32(4):351-62. doi: 10.3109/02656736.2016.1140232. Epub 2016 Feb 24. Int J Hyperthermia. 2016. PMID: 26905963 Review.
-
Hyperthermia and radiotherapy in bladder cancer.Int J Hyperthermia. 2016 Jun;32(4):398-406. doi: 10.3109/02656736.2016.1150524. Epub 2016 Apr 20. Int J Hyperthermia. 2016. PMID: 27097528 Review.
-
The role of hyperthermia as a treatment for non-muscle invasive bladder cancer.Expert Rev Anticancer Ther. 2016;16(2):189-98. doi: 10.1586/14737140.2016.1126515. Epub 2015 Dec 19. Expert Rev Anticancer Ther. 2016. PMID: 26618756 Review.
Cited by
-
Feasibility and safety assessment of magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU)-mediated mild hyperthermia in pelvic targets evaluated using an in vivo porcine model.Int J Hyperthermia. 2019;36(1):1147-1159. doi: 10.1080/02656736.2019.1685684. Int J Hyperthermia. 2019. PMID: 31752562 Free PMC article.
-
Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial.World J Urol. 2022 Apr;40(4):999-1004. doi: 10.1007/s00345-022-03928-1. Epub 2022 Jan 17. World J Urol. 2022. PMID: 35037963 Free PMC article. Clinical Trial.
-
A scalable hyperthermic intravesical chemotherapy (HIVEC) setup for rat models of bladder cancer.Sci Rep. 2022 Apr 29;12(1):7017. doi: 10.1038/s41598-022-11016-y. Sci Rep. 2022. PMID: 35488115 Free PMC article.
-
Lyso-thermosensitive liposomal doxorubicin for treatment of bladder cancer.Int J Hyperthermia. 2017 Nov;33(7):733-740. doi: 10.1080/02656736.2017.1315459. Epub 2017 May 10. Int J Hyperthermia. 2017. PMID: 28540814 Free PMC article.
-
A Multicenter Study of 2-year Outcomes Following Hyperthermia Therapy with Mitomycin C in Treating Non-Muscle Invasive Bladder Cancer: HIVEC-E.Bladder Cancer. 2022 Dec 14;8(4):379-393. doi: 10.3233/BLC-220026. eCollection 2022. Bladder Cancer. 2022. PMID: 38994184 Free PMC article.
References
-
- Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46(4):765–781. - PubMed
-
- Colombo R, Da Pozzo LF, Salonia A, Rigatti P, Leib Z, Baniel J, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. Journal of Clinical Oncology. 2003;21(23):4270–4276. [see comment] - PubMed
-
- Geijsen ED, de Reijke TM, Koning CC, Zum Vorde Sive Vording PJ, de la Rosette JJ, Rasch CR, et al. Combining Mitomycin C and Regional 70 MHz Hyperthermia in Patients with Nonmuscle Invasive Bladder Cancer: A Pilot Study. Journal of Urology. 2015;194:1202–1208. - PubMed
-
- Gofrit ON, Shapiro A, Pode D, Sidi A, Nativ O, Leib Z, et al. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Urology. 2004;63(3):466–471. - PubMed
-
- Hashimoto T, Hisazumi H, Nakajima K, Matsubara F. Studies on endocrine changes induced by 8 MHz local radiofrequency hyperthermia in patients with bladder cancer. Int J Hyperthermia. 1991;7(4):551–557. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical